UPDATE on AMARIN (AMRN) - Losing court battle
The news about Amarin losing the court battle at lease for now was shocking to say the least!! The company spent almost 7 yeas and tested on more than 8,000 people worldwide, spent hundreds of millions of dollars to bring it to the market, but the stock fell 67% in after hour trading to $4.46 . The company said, decision is going to challenged and likely take a long time before we know final outcome. Assuming that, the final verdict is lost in the higher court, those generic still can't market for indicator on which FDA Approved the drug. Below are some of my thoughts: Company is going to appeal the decision on higher court which may go for years. The company says to vigorously pursue all available remedies, including an appeal of the Court’s decision and a preliminary injunction pending appeal to, if an ANDA is approved by FDA. Generics only approved for Triglycerides > 500 which is smaller market than TG <500. So Vascepa’s validity st...